Stay up to date with our latest research, milestones, and company news.
ABILITY Neurotech today announced the first-in-human procedure for its BCI technology. Conducted at the Department for Neurosurgery at TUM University Hospital Rechts der Isar, the procedure represents the first use of ABILITY's neural signal acquisition technology in a live surgical setting.
ABILITY Neurotech has received Investigational Medical Device Dossier (IMDD) approval from the Medical Research Ethics Committee NedMec in the Netherlands to launch its first chronic implantation study of a fully implantable wireless optical-link ECoG BCI in ALS patients.
Months of rigorous testing, validation, and engineering effort captured in one video. From environmental stress tests and impact testing to electrical verification and device soak trials — watch our team put the ABILITY implant through its paces on the road to First-in-Human.
ABILITY Neurotech is born — spun out from the Wyss Center for Bio and Neuroengineering in Geneva, Switzerland. Built on years of pioneering brain-computer interface research, ABILITY launches with a clear mission: to develop a fully implantable speech neuroprosthesis that restores communication for people who have lost the ability to speak. With deep roots in neuroscience and a world-class founding team, ABILITY sets out to bring next-generation BCI technology from the lab to the patient.